Blog Archives

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

June 10, 2019
BÜHLMANN fCAL® ELISA Citation: Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780. Highlights from this Publication “In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who
Continue Reading →

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring.

December 20, 2018

Wei, S. , Tung, C. et al. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553.

Continue Reading →

Clinical Trial Combines New Symptom App with IBDoc

December 17, 2018

Read a recent article from University of Otago on the success of a new smartphone app, IBDSmart, in synergy with BÜHLMANN IBDoc calprotectin home test.

Continue Reading →

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

August 21, 2018

Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663.

Continue Reading →